adplus-dvertising
Connect with us

Investment

Arlington Capital, in Partnership with Management, Announces Investment in Everest Clinical Research Corporation – Business Wire

Published

 on


WASHINGTON & TORONTO–(BUSINESS WIRE)–Arlington Capital Partners (“Arlington Capital” or “Arlington”), a Washington, DC-based private equity firm, and Everest Clinical Research Corporation (“Everest” or the “Company”) today announced that Arlington has made a majority investment in Everest alongside Everest’s founding shareholders and senior management who will continue to lead the Company.

Founded in 2004 and headquartered in Toronto, Canada, Everest is a leading contract research organization (“CRO”) providing a comprehensive suite of mission-critical clinical research services to the worldwide pharmaceutical, biotechnology, and medical device industries across Phase I-IV trials. Throughout the Company’s history, Everest has focused on providing exceptional quality, customer service, and on-time delivery to its partners to advance life-changing research. Everest employs over 300 employees across its Toronto, Ontario, Canada; Little Falls, New Jersey, USA; and Shanghai, China offices.

Malcolm Little, a Partner at Arlington, said, “We are excited to embark upon this new partnership with the impressive Everest team. Everest has built an exceptional organization predicated on continuous innovation, technical excellence, and unwavering quality and customer support. Everest’s expertise in biostatistics and clinical data management together with the Company’s extensive track record of supporting many of the world’s most successful pharmaceutical companies across a diverse array of therapeutic areas and clinical phases provides a strong platform for further growth.”

“We are overjoyed to partner with Arlington as we step forward into our next phase of growth,” said Irene Zhang, Founder and CEO of Everest. “We chose to partner with Arlington because of its long track record of success investing in and scaling healthcare businesses, its deep expertise in the pharmaceutical services sector, and its reputation for partnering with founder-owned and operated businesses. We are extremely pleased to work together with Arlington as they share our vision for expanding Everest’s capabilities to better serve our customers while at the same time maintaining our unique culture. Arlington’s ability to provide significant strategic and financial support will further enable Everest to expand our service lines, grow our employee base, and most importantly, provide best-in-class support to our customers throughout the lifecycle of their clinical trials.”

Erica Son, a Vice President at Arlington, added, “We have been very impressed by the Company’s long track record of outstanding bookings and backlog growth, both of which have grown consistently with new and existing customers through the ongoing COVID-19 pandemic. Furthermore, the Company’s diversified backlog provides significant revenue visibility and embedded growth opportunities.”

About Arlington Capital Partners

Arlington Capital Partners is a Washington, DC-based private equity firm that is currently investing out of Arlington Capital Partners V, L.P., a $1.7 billion fund. The firm has managed approximately $4.0 billion of committed capital via five investment funds. Arlington is focused on middle market investment opportunities in growth industries including healthcare, government services and technology, aerospace & defense, and business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enable Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their Company’s position as leading competitors in their field. www.arlingtoncap.com

About Everest Clinical Research Corporation

Everest Clinical Research Corporation (“Everest”) is a full-service contract research organization (“CRO”) providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device industries. Everest serves some of the best-known companies and works with many of the most advanced drugs, biologics, and medical devices in development today. Founded in 2004, Everest has a strong foundation as a statistical and data management center of excellence. Building on this foundation, Everest has successfully developed and established itself as a full-service CRO. Operating primarily in North America, with headquarters located in Toronto, Ontario, Canada, a second office in Little Falls, New Jersey, USA and a third office in Shanghai, China, Everest is known in the industry for its high quality deliverables, superior customer service, and flexibility in meeting clients’ needs. www.ecrscorp.com

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Investment

Tesla shares soar more than 14% as Trump win is seen boosting Elon Musk’s electric vehicle company

Published

 on

 

NEW YORK (AP) — Shares of Tesla soared Wednesday as investors bet that the electric vehicle maker and its CEO Elon Musk will benefit from Donald Trump’s return to the White House.

Tesla stands to make significant gains under a Trump administration with the threat of diminished subsidies for alternative energy and electric vehicles doing the most harm to smaller competitors. Trump’s plans for extensive tariffs on Chinese imports make it less likely that Chinese EVs will be sold in bulk in the U.S. anytime soon.

“Tesla has the scale and scope that is unmatched,” said Wedbush analyst Dan Ives, in a note to investors. “This dynamic could give Musk and Tesla a clear competitive advantage in a non-EV subsidy environment, coupled by likely higher China tariffs that would continue to push away cheaper Chinese EV players.”

Tesla shares jumped 14.8% Wednesday while shares of rival electric vehicle makers tumbled. Nio, based in Shanghai, fell 5.3%. Shares of electric truck maker Rivian dropped 8.3% and Lucid Group fell 5.3%.

Tesla dominates sales of electric vehicles in the U.S, with 48.9% in market share through the middle of 2024, according to the U.S. Energy Information Administration.

Subsidies for clean energy are part of the Inflation Reduction Act, signed into law by President Joe Biden in 2022. It included tax credits for manufacturing, along with tax credits for consumers of electric vehicles.

Musk was one of Trump’s biggest donors, spending at least $119 million mobilizing Trump’s supporters to back the Republican nominee. He also pledged to give away $1 million a day to voters signing a petition for his political action committee.

In some ways, it has been a rocky year for Tesla, with sales and profit declining through the first half of the year. Profit did rise 17.3% in the third quarter.

The U.S. opened an investigation into the company’s “Full Self-Driving” system after reports of crashes in low-visibility conditions, including one that killed a pedestrian. The investigation covers roughly 2.4 million Teslas from the 2016 through 2024 model years.

And investors sent company shares tumbling last month after Tesla unveiled its long-awaited robotaxi at a Hollywood studio Thursday night, seeing not much progress at Tesla on autonomous vehicles while other companies have been making notable progress.

Tesla began selling the software, which is called “Full Self-Driving,” nine years ago. But there are doubts about its reliability.

The stock is now showing a 16.1% gain for the year after rising the past two days.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Investment

S&P/TSX composite up more than 100 points, U.S. stock markets mixed

Published

 on

 

TORONTO – Canada’s main stock index was up more than 100 points in late-morning trading, helped by strength in base metal and utility stocks, while U.S. stock markets were mixed.

The S&P/TSX composite index was up 103.40 points at 24,542.48.

In New York, the Dow Jones industrial average was up 192.31 points at 42,932.73. The S&P 500 index was up 7.14 points at 5,822.40, while the Nasdaq composite was down 9.03 points at 18,306.56.

The Canadian dollar traded for 72.61 cents US compared with 72.44 cents US on Tuesday.

The November crude oil contract was down 71 cents at US$69.87 per barrel and the November natural gas contract was down eight cents at US$2.42 per mmBTU.

The December gold contract was up US$7.20 at US$2,686.10 an ounce and the December copper contract was up a penny at US$4.35 a pound.

This report by The Canadian Press was first published Oct. 16, 2024.

Companies in this story: (TSX:GSPTSE, TSX:CADUSD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Economy

S&P/TSX up more than 200 points, U.S. markets also higher

Published

 on

 

TORONTO – Canada’s main stock index was up more than 200 points in late-morning trading, while U.S. stock markets were also headed higher.

The S&P/TSX composite index was up 205.86 points at 24,508.12.

In New York, the Dow Jones industrial average was up 336.62 points at 42,790.74. The S&P 500 index was up 34.19 points at 5,814.24, while the Nasdaq composite was up 60.27 points at 18.342.32.

The Canadian dollar traded for 72.61 cents US compared with 72.71 cents US on Thursday.

The November crude oil contract was down 15 cents at US$75.70 per barrel and the November natural gas contract was down two cents at US$2.65 per mmBTU.

The December gold contract was down US$29.60 at US$2,668.90 an ounce and the December copper contract was up four cents at US$4.47 a pound.

This report by The Canadian Press was first published Oct. 11, 2024.

Companies in this story: (TSX:GSPTSE, TSX:CADUSD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending